Laser capture microdissection typically uses fixed, sectioned tissue, limiting both the quality and quantity of recovered RNA. All of the above approaches lead to isolation of the bulk pool of RNA, irrespective of when the RNA was transcribed. TU tagging avoids these limitations by covalently tagging cell type-specific RNA in vivo to enable its subsequent purification from total RNA prepared from a complex tissue.
Alternative genetic-based methods that use in vivo labeling for cell type-specific transcriptome studies include INTACT, TRAP and Ribo-tag [7] [8] [9] [10] . INTACT provides for the purification of cell type-specific nuclei; therefore, isolated RNA exclusively represents the accumulated nuclear pool. However, INTACT has the advantage of allowing simultaneous chromatin landscape or transcription factor association studies (by ChIP-seq), and therefore it provides extra information on gene regulatory networks. TRAP and Ribo-tag examine ribosomal protein-bound mRNA and are therefore especially useful as surrogate approaches to study global protein translation. These methods may not detect noncoding RNAs (ncRNA) including miRNAs. In contrast, TU tagging labels all newly transcribed RNA and thus enables simultaneous studies of mRNA and ncRNA. Mouse TU tagging is also designed as a modular system, being readily combined with the many existing Cre lines and usually eliminating the need to develop new transgenic lines before experiments can be pursued. As each of these alternative methods, including TU tagging, have unique advantages, a researcher should carefully consider which approach would most efficiently answer their questions of interest before pursuing a new study.
Experimental design
There are three stages to the presented mouse TU-tagging protocol (Fig. 1) . The first stage describes the delivery of 4TU to initiate in vivo RNA labeling. The second stage describes, in detail, the molecular biology protocol for isolating TU-tagged RNA and preparing libraries for Illumina sequencing. The third stage outlines one straightforward bioinformatics approach to quickly process raw Illumina data into a table of enriched or differentially expressed TU-tagged transcripts. Successful completion of each stage will require that the research team have at least some experience in each of mouse genetics, molecular biology and statistical analysis of large data sets.
TU tagging takes advantage of the many existing cellspecific and tissue-specific Cre lines and our recently developed CA > GFPstop > HA-UPRT transgene to direct spatially restricted UPRT expression in the desired Cre-positive cell lineage 1 . This transgene incorporates a broadly expressed, constitutively active (CA) chicken β-actin/CMV promoter driving a loxP-GFP3stop-loxP cassette, followed by a hemagglutinin (HA) epitopetagged UPRT cDNA. The GFP-3stop cassette includes three SV40 polyadenylation sequences to prevent transcription of HA-UPRT until the cassette is excised by Cre activity. In mice carrying both transgenes, UPRT becomes permanently expressed in the Cre-expressing cell lineage. By GFP immunostaining, we demonstrated that the CA > GFPstop > HA-UPRT has widespread promoter activity in embryonic and postnatal tissues 1 . Nevertheless, Cre-induced expression of HA-UPRT should be confirmed before undertaking TU tagging in a new cell type. The tissue-specific:Cre line should be chosen carefully, as UPRT will be permanently expressed in any cell lineage that expressed Cre at any point in its development. Where available, the use of a tamoxifen-inducible Cre-ER line may facilitate tighter control of cell type specificity 11 . Tissues are sectioned and immunostained with HA antibodies (to detect UPRT) and a cell-specific antibody that labels the cells in which UPRT induction is expected 1 For reliable and reproducible TU-tagging experiments, both the UPRT and Cre transgene copy numbers should be consistent between experimental repeats. Therefore, for most experiments, it is most convenient to use double-heterozygous UPRT;Cre animals. If possible, interbreed homozygous CA > GFPstop > HA-UPRT, which are viable and fertile, with homozygous Cre animals. All resulting progeny will be heterozygous for both the CA > GFPstop > HA-UPRT and Cre transgenes, requiring no genotyping and, as is especially useful for embryonic studies, allowing immediate pooling of samples (except for sex-specific studies). Mice are then injected with 4TU at a desired postnatal age or at a desired stage of pregnancy to provide temporal control of TU tagging.
There are two distinct TU-tagging experimental designs. In 'Type I' experiments, transcript levels are compared between the TU-tagged RNA ('pure') and the total RNA ('total') from which the TU-tagged RNA was purified. This approach reports on how enriched each transcript is within the UPRT-expressing cells compared with the total tissue from which the RNA was prepared. Therefore, this experimental design is ideal for observational studies when the goal is to characterize a given cell type's unique active transcriptome during a defined period of 4TU exposure. The maximum fold enrichment of a transcript is the inverse of the cell type's fractional representation within the starting material. Perfect enrichment, however, is never achieved, as there is always limited background labeling in non-UPRT-expressing cells 1 . The choice of starting material is of paramount importance. A careful organ or tissue dissection that enriches for the cell type of interest will avoid failure to detect cell-specific transcripts expressed at low levels. However, if the cell type being studied comprises more than ~33% of the starting material, the maximum fold enrichment will be low and therefore statistical significance will be more difficult to achieve. Note that short-lived transcripts will be over-represented in the pure compared with the total RNA, which could generate a bias when defining genes with cell type-enriched expression.
An alternative control for nascent RNA bias is to expose control mice to 4-thiouridine (4TUd), in parallel with the littermates exposed to 4TU. Whereas 4TU requires UPRT to be incorporated into nascent RNA, 4TUd will be added to newly synthesized RNA in all cells 12 . Thus, a comparison can be made between pure RNA from experimental mice with cell type-specific 4TU and mice with all nascent RNA thio-labeled 4TUd. For example, tissue-specific:Cre; CA > GFPstop > HA-UPRT littermate mice are injected with either 4TU or 4TUd, and then the organ of interest is collected after a fixed period. TU-tagged RNA is purified and sequenced in each case. Genes with relatively more reads in the 4TU-exposed mice are more abundantly expressed in the cell type in which Cre has been active. The workflow for a Type I experiment using this approach would be similar to the 'Type II' experiment described below (only pure TU-tagged RNA is sequenced in each case). Regardless, the output of a Type I experiment is a table of statistically significant enriched and depleted transcripts in the UPRT-expressing cells.
In Type II experiments, a transcriptome comparison is performed between two or more purified, TU-tagged RNA samples isolated from animals that were differentially treated. As examples, the differences could be mutant versus control mice, before and after a drug delivery or induced physiologic response (e.g., the aforementioned spleen LPS-response experiment), or a comparison between two or more treatments/manipulations. Type II experiments are also useful when comparing transcriptomes of the same cell type in different organs of the same animal (e.g., our organ-specific endothelial experiments). The output in Type II experiments is a table of differentially expressed genes. For both Type I and Type II experiments, the molecular biology protocol is nearly identical, with the major difference being the samples prepared for sequencing (Type I = pure versus total, Type II = pure versus pure). The bioinformatics analysis outlined here conveniently uses the identical workflow for both experimental types, but the output is interpreted as either fold enrichment (Type I) or fold change (Type II). The bioinformatics analysis example presented is from a Type I experiment characterizing postnatal day 6 (P6) brain endothelial and macrophage/microglia transcriptomes 1 .
Regardless of design, it is preferable to predefine a set of tissuespecific positive control transcripts. This will empower the analysis and allow an immediate assessment of the experiment's data quality. For example, in our endothelial transcriptome experiments, we used 13 well-known positive control endothelial genes: Tie1 and Thsd1 . The positive control transcripts should cluster among the most enriched in a Type I experiment. For de novo transcriptome definition experiments, a gene ontology term analysis should be performed (using, e.g., Princeton Gene Ontology Tools (http://go.princeton.edu/)) on the full set of enriched transcripts to verify that expected GO terms for the studied cell type are over-represented. The statistically enriched transcripts can also be examined by using a gene expression database such as Eurexpress 13 (http://www. eurexpress.org/) to confirm the preponderance of enriched transcripts expressed in the Cre-labeled cell lineage. For all experiments, at least two biological replicates of each sample (e.g., experimental and control) should be sequenced.
The workflow for a typical TU-tagging experiment begins with 4TU delivery (Stage 1; Fig. 1) . Typically, the tissue-specific:Cre and CA > GFPstop > HA-UPRT double transgenic adults or postnatal pups are injected with 4TU and collected 4-6 h later. We have observed a drop in labeling if the tissue is collected ≥ 12 h after injection, enabling pulse-chase experiments to study transcriptome dynamics. For embryonic studies, pregnant mice carrying double transgenic embryos are exposed to 4TU for at least 6 h. Embryonic studies use a longer 4TU exposure period because of an anticipated time lag for the compound to cross the placental barrier into embryonic or fetal circulation. The desired tissue is collected and total RNA is isolated in ~3 h, depending on the number of tissue samples collected. Either two biological replicates (Type I experiments) or two experimental and two matched control RNA samples (Type II experiments) can be comfortably processed at one time by the subsequent molecular biology steps to Illumina sequencing (Stage 2).
Stage 2 ( Fig. 1 ) requires at least 10 µg of RNA from each sample. Less RNA may be used, but it may yield inconsistent outcomes. First, we deplete the RNA from rRNA (rRNA) by using Ribo-Zero kits, as described in the PROCEDURE. Alternative approaches include an RNase H method 14 that is likely to be less expensive over the long run and has worked well in pilot experiments. Both the Ribo-Zero and RNase H methods can recover pre-mRNAs, mRNAs and ncRNAs, and they can therefore provide a broad report of transcriptomes. However, instead of rRNA depletion, poly(A) mRNA can be purified or oligo(dT) can be used to prime first-strand cDNA synthesis from non-rRNA-depleted RNA samples. These two methods fail to recover pre-mRNA and ncRNA, but they produce a higher fraction of exon reads, which are scored by conventional bioinformatics approaches including the method outlined in this protocol.
The RNA is then fragmented (optional for Type II experiments). RNA fragmentation increases the relative number of thio-labeled RNA fragments from UPRT-expressing cells compared with spuriously but infrequently labeled transcripts from non-UPRTexpressing cells. Fragmenting the RNA before purification not only reduces background but will also remove the capture bias for large (uridine-rich) RNA molecules that was observed in earlier experiments 2 . RNA fragmentation is not required for most Type II experiments because usually all the pure RNA samples will have similar background and large-transcript bias that is negated by the bioinformatics analysis. TU-tagged RNA is then biotinylated and affinity-purified by using streptavidin-conjugated magnetic beads. Fragmentation, biotinylation and purification together take ~6 h. Note that TU-tagged RNA concentrations are usually too low to be quantified, and thus the entire amount of TU-tagged RNA of each sample is used for cDNA synthesis, amplification and the addition of distinct Illumina index adaptors. For Type I experiments, an aliquot of total fragmented RNA is also prepared for sequencing. The indexed samples are pooled at equimolar concentrations and stored at − 20 °C until Illumina sequencing.
Upon the return of the raw RNA-sequencing data, a bioinformatics analysis is performed (Stage 3). Many different analysis options are available; users should consider their experimental needs when designing a workflow, and they should consult with bioinformatics experts as necessary. Here we describe one straightforward workflow that uses popular software packages to characterize mRNAs. This approach efficiently provides a basic analysis while requiring only minimal knowledge of Unix commands and the R statistical programming language. Illumina sequencing provides raw reads data as a series of fastq-formatted files. These files are concatenated and processed on a Unix server with multicore processing. By using the alignment and mapping tools TopHat2 (ref. 15) , SAMtools 16 and HTSeq 17 , raw reads mapping to exons are assigned to each gene within a mouse reference genome, producing a tab-delimited text file that contains the total number of counts (reads) for each gene. Each file is downloaded to a personal computer and opened in Excel (or other spreadsheet software). The counts data for each data set are combined into a single file and resaved as a tab-delimited file for import into R. We suggest using the freely available RStudio package (http://www. rstudio.com/) to provide a convenient R workspace. We suggest the DESeq package 18 as one tool for identifying enriched (Type I) or differentially expressed (Type II) genes. Briefly, DESeq uses count-based data and a negative binomial distribution to statistically determine genes with differential expression levels between data sets, including replicates. DESeq returns a table with adjusted P values (Benjamini-Hochberg correction method) indicating whether transcripts from each corresponding gene are differentially present between data sets. A table showing only statistically different genes is generated, which can be further analyzed by R or exported back to Excel or other software. As mentioned, some experience with Illumina data, Unix commands and R will facilitate following this protocol. Available TopHat2/HTSeq/ DESeq manuals and vignettes should be consulted to help lessexperienced researchers to become familiar with the programs and their parameters.
Limitations
Applications of mouse TU tagging by using the CA > GFPstop > HA-UPRT mice are limited by the availability of an appropriate Crerecombinase-expressing transgenic line. Certain experiments may be difficult or impossible if there are insufficient numbers of UPRT-expressing cells in the tissue sample used to prepare the total RNA. We have not determined the lower limit, but our chimeric mouse experiments suggest that TU-tagged RNA can be recovered if even 1% of the cells express UPRT 1 . Although initial experiences using Cre/lox-driven mouse TU tagging agree with this result, researchers should proceed with caution when performing TU tagging in rare cell types. Finally, transcripts with unusually low turnover may be infrequently labeled or not labeled during short 4TU exposure periods, and therefore they are excluded from tissue-specific expression analyses. 
MaterIals

REAGENTS
• • • • • • • • • • • • • • • • • •• • • • • • • • • • • • • • • • • • • • • •
2|
Inject 4TU intraperitoneally by using a tuberculin syringe and a 27-G needle.
3|
Allow at least 4 h of 4TU exposure before tissue collection for adults and pups and 6 h for pregnant females.  crItIcal step Exposure time can be varied depending on the experiment being performed. Labeling can be detected in as little as 2 h after 4TU exposure to postnatal mice, but with considerably reduced yield. We have not defined the minimum exposure period for embryonic studies. We observe decreased labeling when waiting longer than 12 h after 4TU injection.
4| Dissect out the organ or tissue of interest, transfer it immediately into a 1.5-ml microcentrifuge tube and flash-freeze it in liquid nitrogen. Continue with RNA preparation or store it at − 80 °C.  pause poInt Frozen tissue can be stored at − 80 °C indefinitely.
rna purification • tIMInG 2-3 h  crItIcal From this point on, care should be taken to maintain RNase-free conditions. Benchtop surfaces should be thoroughly cleaned, RNase-free tubes and tips should be used and gloves should be worn at all times.
5|
Precool the centrifuge to 4 °C.
6|
Homogenize the tissue in a 1.5-ml tube by using a Kontes pestle and 500 µl of TRIzol per 100 mg of tissue until it is completely solubilized. ! cautIon TRIzol is toxic and should be handled in a fume hood. Gloves and a lab coat should be worn.
? trouBlesHootInG 7| Add 500 µl of additional TRIzol and vortex the tissue mixture. Incubate the tube for 5 min at room temperature (~22 °C).
8|
Add 200 µl of chloroform and vortex it for 15 s. Incubate the mixture for 2-3 min at room temperature. ! cautIon Wear gloves and use a fume hood when you are working with chloroform.  crItIcal step The extended chloroform vortex is important for high RNA yield and quality.
22| Fragment the entire 50 µl of the rRNA-depleted RNA in a 100-µl final volume according to the NEBNext RNA fragmentation kit protocol. Use thin-walled PCR tubes and a thermocycler to incubate at 85 °C for 4 min with cooling to 10 °C before proceeding. 
23|
Isolation of biotinylated rna
• tIMInG 1 h 28| Isolate biotinylated RNA from nonlabeled RNA according to the µMacs streptavidin kit's directions, with the exception of using 100 mM 2-mercaptoethanol instead of DTT for the elution step. Elute it twice with 100 µl of preheated 100 mM 2-mercaptoethanol and pool the eluates. ! cautIon 2-mercaptoethanol is toxic and should be used in a fume hood while you are wearing gloves and a lab coat. Avoid inhalation.
29|
Purify the eluted biotinylated TU-tagged RNA by using RNeasy MinElute columns, eluting in 12 µl of RNase-free H 2 O. Attempt to measure the RNA concentration via a Qubit and/or Bioanalyzer.  crItIcal step The yield of TU-tagged purified RNA is usually below detection limits. Essentially all the RNA, which is recovered in ~10 µl, is used for the subsequent cDNA synthesis step.  pause poInt (end of day 2) RNA should be frozen and stored at − 80 °C indefinitely. Optionally, proceed with library synthesis. 
Illumina library preparation
32|
Amplify the cDNA samples with 12-15 PCR cycles by following the directions in section 3.E of the ScriptSeq v2 manual.  crItIcal step Although we typically require 15 cycles to generate sufficient DNA, limiting PCR cycles when possible will increase library diversity and improve downstream analyses. Use different index reverse PCR primers from the ScriptSeq index PCR primers set for each RNA sample.
33|
Purify the RNA-seq libraries with AMPure XP beads according to the directions in section 3.F of the ScriptSeq v2 manual. Elute samples in 20 µl of RNase-free water.
34|
Qubit-quantify each library. Start with 1 µl and incrementally increase up to 5 µl until a Qubit reading can be attained. ? trouBlesHootInG 35| Mix equimolar amounts of each library (typically four, but up to six, all synthesized with their distinct index primers) to a total concentration and volume requested by your sequencing facility, and then submit the pooled libraries for Illumina sequencing. If necessary, use a MinElute reaction cleanup column to concentrate the pooled RNA-seq libraries. We recommend adding Tween-20 to a final concentration of 1% (vol/vol) to prevent the DNA from adhering to tube walls. We typically perform single-read sequencing on a single lane of an Illumina HiSeq 2000. If paired-end reads are desired, the bioinformatics protocol described below should be modified accordingly.
processing Illumina data • tIMInG 6-12 h 36| Download fastq files onto a Unix server. If multiple fastq files are produced for a given sample, use the Unix command 'cat' to concatenate them into a single file. You will produce one fastq file per library sequenced, which we name by sample run and bar code (e.g. 1234_ATCGAC.fastq). Assess the quality of your reads (e.g., with FastQC) and trim for quality and adaptor sequences if necessary. Note the number of total raw reads for each fastq file. 
37|
41|
Create a combined counts table in Excel for all the samples to be compared. The instructions that follow are for a Type I experiment performing a comparison between two sets of total RNA and TU-tagged pure RNA. Start with one of the total sets. Copy the entire counts column from the corresponding pure.htseq file into the adjacent third column. Do likewise with the second total and pure data sets. This spreadsheet will now have five columns, the first being gene symbols and the adjacent four containing the corresponding counts data from each sample. Name the columns 'Symbol', 'T1', 'P1', 'T2' and 'P2' . Save as a tab-delimited text file (tutag_counts.txt). An example counts table is included as supplementary table 1.
42| Import the tab-delimited counts table into R studio. Note that everything following the ' > 's below are the R commands.
The head command will show the first ten rows of imported table, which will confirm that the formatting is correct.
> countsTable < -read.delim ( "tutag_counts.txt", header = TRUE, row.names = 1)
> head( countsTable )
43| Describe the organization of your counts table (i.e., which columns correspond to which samples). For the Type I experiment example outlined here, the condition table indicates the column position of each pure sample with a 'P' and each total sample position with a 'T' .
44|
Install the DESeq package into R studio. Then, load the DESeq library.  crItIcal step Failure to filter low-count genes may prevent DESeq from functioning.
47| Estimate the effective library size (normalization).
> cdsFilt < -estimateSizeFactors( cdsFilt )
48| Estimate the dispersions of the data set.
> cdsFilt < -estimateDispersions( cdsFilt )
49| Determine differentially expressed genes. The head command will display the DESeq analysis of the first ten rows of your counts table, including the Benjamini-Hochberg adjusted P value ('padj') for each gene ('id').
> res = nbinomTest( cdsFilt, "T", "P") > head(res) 50| Generate a scatter plot of the data by plotting the log fold change against the mean normalized counts. A graph will be produced that shows each transcript plotted as factors of the mean normalized counts and the log 2 fold change. Differentially expressed transcripts (with a false discovery rate (FDR) of 10%) are highlighted in magenta. An example plot is shown in Figure 2 (green dots additionally indicate positive control genes).
> plotMA(res)
51| Filter the data for differentially expressed genes, according to a chosen FDR threshold. Here the adjusted P value is set at < 0.05, according to convention.
> resSig = res[ res$padj < 0.05, ]
52|
Save the output to an exportable file.
> write. 
antIcIpateD results
This protocol includes example data from a successful experiment describing the P6 brain Tie2:Cre-lineage transcriptome (endothelial cells and macrophages/microglia). P6 Tie2:Cre;CA > GFPstop > HA-UPRT double-transgenic mice were given a 400 mg kg − 1 s.c. 4TU injection and killed after 6 h. The whole brain was removed for RNA preparation. We used 50 µg of starting RNA from each of two littermate pups. After rRNA removal and RNA fragmentation, we recovered 1.1 and 1.3 µg of rRNA-depleted total 1 and total 2 RNA samples, respectively. TU-tagged RNA was purified from both samples. The two total and two pure RNA preparations were used to synthesize bar-coded Illumina libraries that were pooled and sequenced on one lane of a HiSeq 2000. We obtained 39 million total reads for the total 1 sample, 19 million total reads for the pure 1 sample, 34 million total reads for the total 2 sample and 33 million total reads for the pure 2 sample. Of those reads, 27 million, 14 million, 24 million and 24 million reads aligned to the mouse genome, respectively. After HTSeq read mapping, DESeq analysis and expression-level filtering, we identified 913 differentially expressed genes that were more than twofold enriched in Tie2:Cre-lineage cells. The HTSeq-generated counts tables for this experiment are included as supplementary table 1. A DESeq/R-generated scatter plot highlighting differentially expressed genes and positive control genes is shown in Figure 2 . supplementary table 2 shows the top 20 most-enriched transcripts and supplementary table 3 shows the statistical analysis of the entire transcriptome.
